Orphazyme to collaborate with The Michael J. Fox Foundation on Parkinson’s disease research

by | Jul 17, 2020

Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announces that it will join The Michael J. Fox Foundation’s (MJFF) Parkinson’s Disease Research Tools Consortium. The group brings together experts from the medical community and industry to identify and develop new pre-clinical tools to address unmet research needs and accelerate experiments. 

Press inquiries should be adressed to:

Sten Verland, PhD MSc

General Partner